Axogen Will Start Prostate Nerve Repair Market Development In 2027, Citing Early Results From 220 Patients

The company says about 80% of patients with six months of follow-up beat expected erectile recovery, and prostate sits outside its guidance.

Share
Axogen Will Start Prostate Nerve Repair Market Development In 2027, Citing Early Results From 220 Patients

Axogen, which sells products surgeons use to repair damaged peripheral nerves, will begin market development for prostate nerve reconstruction in 2027, CEO Michael Dale said on the company's earnings call Wednesday. Over 220 patients have received the procedure with its Avance nerve graft across 15 clinical development sites, he said.

Early outcomes from 117 patients

Dale said 117 of those patients have at least six months of follow-up: 86 grafted on one side and 31 on both. No graft or procedure-related complications were reported.

Among them, surgeons report that about 80% reached better than expected erectile function recovery, which Dale defined as a SHIM score of 15 or higher on a 25-point scale. Over 95% achieved pad-free urinary continence at or above expected levels. Dale said the results show "an exceptional benefit to risk ratio."

The baseline is weak. Dale said men undergoing unilateral non-nerve-sparing prostatectomy historically recover erectile function in only 33% to 56% of cases, and those undergoing bilateral procedures have less than a 13% chance.

Targeting and margins

Asked by a Bank of America analyst how many of roughly 110,000 yearly robotic prostatectomies Axogen could target at launch, executive Jens said the company is building a targeting algorithm. It will focus on academic centers, high-volume centers and centers doing a mix of unilateral and bilateral reconstructions.

Dale said prostate grafts are shorter than breast grafts, so each donor yields more, and he does not expect the same margin pressure. CFO Lindsey Hartley said production benefits probably will not show up in 2027.

Dale said the value proposition is clearest for unilateral or bilateral non-nerve-sparing patients, and that broader groups such as active surveillance patients will come later.

Outside guidance, with dates set

Dale said prostate is not in current or long-range guidance, and an update is planned for the first quarter of 2027. The company will hold a prostate call on November 9 with two urologists, and will detail the financials and logistics of the plan at a March 2027 investor day.

The news came with third-quarter results: revenue of $75.8 million, up 26.2% from a year earlier, and GAAP net income of $2.3 million. Hartley said 2026 revenue is now expected to be at least $290 million, including at least $7 million from BioCircuit, which Axogen bought on October 1. The company had $350.1 million in cash and investments at September 30.

The November 9 call, with two urologists, is where Axogen has said it will lay out the clinical outcomes and market research behind the decision.

Sources

More on Axogen

All Axogen (AXGN) coverage →